Nurix Therapeutics (NASDAQ:NRIX) Upgraded at Leerink Partnrs

Leerink Partnrs upgraded shares of Nurix Therapeutics (NASDAQ:NRIX) to a hold rating in a research note issued to investors on Monday morning,Zacks.com reports. Leerink Partnrs also issued estimates for Nurix Therapeutics’ Q1 2025 earnings at ($0.89) EPS and Q2 2025 earnings at ($0.93) EPS.

Several other research firms have also issued reports on NRIX. Needham & Company LLC decreased their target price on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, January 29th. Royal Bank of Canada boosted their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. JPMorgan Chase & Co. decreased their target price on Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. Morgan Stanley boosted their target price on Nurix Therapeutics from $16.00 to $17.00 and gave the stock an “equal weight” rating in a research report on Monday, February 3rd. Finally, Stifel Nicolaus lifted their price objective on Nurix Therapeutics from $34.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. Three analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.88.

Nurix Therapeutics Stock Performance

Shares of NRIX stock opened at $13.90 on Monday. The stock’s fifty day moving average is $17.22 and its 200-day moving average is $20.93. The stock has a market capitalization of $1.05 billion, a PE ratio of -4.81 and a beta of 2.18. Nurix Therapeutics has a 52 week low of $11.90 and a 52 week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. As a group, analysts forecast that Nurix Therapeutics will post -2.99 earnings per share for the current fiscal year.

Insider Transactions at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 2,811 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $55,798.35. Following the transaction, the chief financial officer now directly owns 39,549 shares of the company’s stock, valued at approximately $785,047.65. The trade was a 6.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gwenn Hansen sold 3,690 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the transaction, the insider now directly owns 55,937 shares in the company, valued at $1,110,349.45. The trade was a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,326 shares of company stock worth $213,449 in the last 90 days. Corporate insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company grew its holdings in Nurix Therapeutics by 2.1% in the 4th quarter. The Manufacturers Life Insurance Company now owns 31,025 shares of the company’s stock valued at $585,000 after buying an additional 642 shares in the last quarter. Corebridge Financial Inc. grew its holdings in Nurix Therapeutics by 2.3% in the 4th quarter. Corebridge Financial Inc. now owns 34,907 shares of the company’s stock valued at $658,000 after buying an additional 770 shares in the last quarter. Kennedy Capital Management LLC grew its holdings in Nurix Therapeutics by 0.7% in the 4th quarter. Kennedy Capital Management LLC now owns 114,623 shares of the company’s stock valued at $2,159,000 after buying an additional 785 shares in the last quarter. US Bancorp DE grew its holdings in Nurix Therapeutics by 144.7% in the 4th quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after buying an additional 842 shares in the last quarter. Finally, Summit Investment Advisors Inc. grew its holdings in Nurix Therapeutics by 13.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company’s stock valued at $138,000 after buying an additional 877 shares in the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.